IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508

Journal of Experimental Medicine

Volumn 202, Issue 9, 2005, Pages 1289-1300

  Eun, Sook Hwang ^a,b   Hong, Jeong Ho ^d   Glimcher, Laurie H ^b,c,e,f  

^a Ewha Womans University   (South Korea)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE I; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 2; PROTEIN; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; TH1 CELL; TRANSCRIPTION INITIATION;

ANIMALS; BASE SEQUENCE; CASEIN KINASE I; CELL DIFFERENTIATION; CELL LINE, TUMOR; CLONE CELLS; DIMERIZATION; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SERINE; T-BOX DOMAIN PROTEINS; TH1 CELLS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS;

EID: 27744461314     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20051044     Document Type: Article

References (76)

1. Schimpl, A., I. Berberich, B. Kneitz, S. Kramer, B. Santner-Nanan, S. Wagner, M. Wolf, and T. Hunig. 2002. IL-2 and autoimmune disease. Cytokine Growth Factor Rev. 13:369-378.
2. Zhu, J., J. Cote-Sierra, L. Guo, and W.E. Paul. 2003. Stat5 activation plays a critical role in Th2 differentiation. Immunity. 19:739-748.
3. Ragheb, J.A., M. Deen, and R.H. Schwartz. 1999. CD28-mediated regulation of mRNA stability requires sequences within the coding region of the IL-2 mRNA. J. Immunol. 163:120-129.
4. Durand, D., J. Shaw, M. Bush, R. Replogle, R. Belagaje, and G. Crabtree. 1988. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol. Cell. Biol. 8:1715-1724.
5. Siebenlist, U., D.B. Durand, P. Bressler, N.J. Holbrook, C.A. Norris, M. Kamoun, J.A. Kant, and G.R. Crabtree. 1986. Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol. Cell. Biol. 6:3042-3049.
6. Jain, J., C. Loh, and A. Rao. 1995. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:333-342.
7. Serfling, E., A. Avots, and M. Neumann. 1995. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim. Biophys. Acta. 1263:181-200.
8. Powell, J.D., J.A. Ragheb, S. Kitagawa-Sakakida, and R.H. Schwartz. 1998. Molecular regulation of interleukin-2 expression by CD28 costimulation and anergy. Immunol. Rev. 165:287-300.
9. Novak, T.J., P.M. White, and E.V. Rothenberg. 1990. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res. 18:4523-4533.
10. Peng, S.L., A.J. Gerth, A.M. Ranger, and L.H. Glimcher. 2001. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity. 14:13-20.
11. Kontgen, F., R.J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9:1965-1977.
12. Liou, H.C., Z. Jin, J. Tumang, S. Andjelic, K.A. Smith, and M.L. Liou. 1999. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int. Immunol. 11:361-371.
13. Grundstrom, S., P. Anderson, P. Scheipers, and A. Sundstedt. 2004. Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells. J. Biol. Chem. 279:8460-8468.
14. Lai, J.H., G. Horvath, J. Subleski, J. Bruder, P. Ghosh, and T.H. Tan. 1995. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell. Biol. 15:4260-4271.
15. Neumann, M., T. Grieshammer, S. Chuvpilo, B. Kneitz, M. Lohoff, A. Schimpl, B.R. Franza Jr., and E. Serfling. 1995. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J. 14:1991-2004.
16. Ghosh, P., T.H. Tan, N.R. Rice, A. Sica, and H.A. Young. 1993. The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc. Natl. Acad. Sci. USA. 90:1696-1700.
17. Parra, E., K. McGuire, G. Hedlund, and M. Dohlsten. 1998. Overexpression of p65 and c-Jun substitutes for B7-1 costimulation by targeting the CD28RE within the IL-2 promoter. J. Immunol. 160:5374-5381.
18. Herndon, T.M., Y.T. Juang, E.E. Solomou, S.W. Rothwell, M.F. Gourley, and G.C. Tsokos. 2002. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin. Immunol. 103:145-153.
19. Rao, S., S. Gerondakis, D. Woltring, and M.F. Shannon. 2003. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J. Immunol. 170:3724-3731.
20. Kahn-Perles, B., C. Lipcey, P. Lecine, D. Olive, and J. Imbert. 1997. Temporal and subunit-specific modulations of the Rel/NF-kappaB transcription factors through CD28 costimulation. J. Biol. Chem. 272:21774-21783.
21. Lederer, J.A., J.S. Liou, M.D. Todd, L.H. Glimcher, and A.H. Lichtman. 1994. Regulation of cytokine gene expression in T helper cell subsets. J. Immunol. 152:77-86.
22. Dorado, B., P. Portoles, and S. Ballester. 1998. NF-kappaB in Th2 cells: delayed and long-lasting induction through the TCR complex. Eur. J. Immunol. 28:2234-2244.
23. Yui, M.A., G. Hernandez-Hoyos, and E.V. Rothenberg. 2001. A new regulatory region of the IL-2 locus that confers position-independent transgene expression. J. Immunol. 166:1730-1739.
24. Bruniquel, D., and R.H. Schwartz. 2003. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 4:235-240.
25. Ward, S.B., G. Hernandez-Hoyos, F. Chen, M. Waterman, R. Reeves, and E.V. Rothenberg. 1998. Chromatin remodeling of the interleukin-2 gene: distinct alterations in the proximal versus distal enhancer regions. Nucleic Acids Res. 26:2923-2934.
26. Rothenberg, E.V., and S.B. Ward. 1996. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc. Natl. Acad. Sci. USA. 93:9358-9365.
27. Attema, J.L., R. Reeves, V. Murray, I. Levichkin, M.D. Temple, D.J. Tremethick, and M.F. Shannon. 2002. The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T cell activation. J. Immunol. 169:2466-2476.
28. Chen, X., J. Wang, D. Woltring, S. Gerondakis, and M.F. Shannon. 2005. Histone dynamics on the interleukin-2 gene in response to T-cell activation. Mol. Cell. Biol. 25:3209-3219.
29. Rao, S., E. Procko, and M.F. Shannon. 2001. Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J. Immunol. 167:4494-4503.
30. Himes, S.R., L.S. Coles, R. Reeves, and M.F. Shannon. 1996. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity. 5:479-489.
31. Wang, W., W.F. Tam, C.C.W. Hughes, S. Rath, and R. Sen. 1997. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity. 6:165-174.
32. Sundstedt, A., M. Sigvardsson, T. Leanderson, G. Hedlund, T. Kalland, and M. Dohlsten. 1996. In vivo anergized CD4 T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc. Natl. Acad. Sci. USA. 93:979-984.
33. Barton, K., N. Muthusamy, M. Chanyangam, C. Fischer, C. Clendenin, and J.M. Leiden. 1996. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature. 379:81-85.
34. Juang, Y.T., Y. Wang, E.E. Solomou, Y. Li, C. Mawrin, K. Tenbrock, V.C. Kyttaris, and G.C. Tsokos. 2005. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115:996-1005.
35. Tenbrock, K., Y.T. Juang, M.F. Gourley, M.P. Nambiar, and G.C. Tsokos. 2002. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. 169:4147-4152.
36. Powell, J.D., C.G. Lerner, G.R. Ewoldt, and R.H. Schwartz. 1999. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol. 163:6631-6639.
37. Yasui, D.H., T. Genetta, T. Kadesch, T.M. Williams, S.L. Swain, L.V. Tsui, and B.T. Huber. 1998. Transcriptional repression of the IL-2 gene in Th cells by ZEB. J. Immunol. 160:4433-4440.
38. Tzachanis, D., G.J. Freeman, N. Hirano, A.A. van Puijenbroek, M.W. Delfs, A. Berezovskaya, L.M. Nadler, and V.A. Boussiotis. 2001. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2:1174-1182.
39. Szabo, S.J., S.T. Kim, G.L. Costa, X. Zhang, G.C. Fathman, and L.H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 100:655-669.
40. Szabo, S.J., B.M. Sullivan, C. Stemmann, A.R. Satoskar, B.P. Sleckman, and L.H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 295:338-342.
41. Szabo, S.J., B.M. Sullivan, S.L. Peng, and L.H. Glimcher. 2003. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21:713-758.
42. Hwang, E.S., S.J. Szabo, P.L. Schwartzberg, and L.H. Glimcher. 2005. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science. 307:430-433.
43. Sullivan, B.M., A. Juedes, S.J. Szabo, M. von Herrath, and L.H. Glimcher. 2003. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl. Acad. Sci. USA. 100:15818-15823.
44. Juedes, A., E. Rodrigo, L. Togher, L.H. Glimcher, and M. von Herrath. 2004. T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J. Exp. Med. 199:1153-1162.
45. Dajani, R., E. Fraser, S.M. Roe, N. Young, V. Good, T.C. Dale, and L.H. Pearl. 2001. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105:721-732.
46. Cohen, P., and S. Frame. 2001. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2:769-776.
47. Rooney, J.W., Y.L. Sun, L.H. Glimcher, and T. Hoey. 1995. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol. Cell. Biol. 15:6299-6310.
48. Mehta, D.S., A.L. Wurster, A.S. Weinmann, and M.J. Grusby. 2005. NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc. Natl. Acad. Sci. USA. 102:2016-2021.
49. Doi, T.S., T. Takahashi, O. Taguchi, T. Azuma, and Y. Obata. 1997. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J. Exp. Med. 185:953-961.
50. Scully, K.M., E.M. Jacobson, K. Jepsen, V. Lunyak, H. Viadiu, C. Carriere, D.W. Rose, F. Hooshmand, A.K. Aggarwal, and M.G. Rosenfeld. 2000. Allosteric effects of Pit-1 DNA sites on long-term repression in cell type specification. Science. 290:1127-1131.
51. Staal, F.J., B.M. Burgering, M. van de Wetering, and H.C. Clevers. 1999. Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int. Immunol. 11:317-323.
52. Giles, R.H., J.H. van Es, and H. Clevers. 2003. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta. 1653:1-24.
53. Avni, O., D. Lee, F. Macian, S.J. Szabo, L.H. Glimcher, and A. Rao. 2002. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 3:643-651.
54. Mullen, A.C., A.S. Hutchins, F.A. High, H.W. Lee, K.J. Sykes, L.A. Chodosh, and S.L. Reiner. 2002. Hlx is induced by and genetically interacts with T-bet to promote heritable Th1 gene induction. Nat. Immunol. 3:652-658.
55. Townsend, M.J., A.S. Weinmann, J.L. Matsuda, R. Salomon, P.J. Farnham, C.A. Biron, L. Gapin, and L.H. Glimcher. 2004. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 20:477-494.
56. Cho, J.Y., V. Grigura, T.L. Murphy, and K. Murphy. 2003. Identification of cooperative monomeric Brachyury sites conferring T-bet responsiveness to the proximal IFN-gamma promoter. Int. Immunol. 15:1149-1160.
57. Shnyreva, M., W.M. Weaver, M. Blanchette, S.L. Taylor, M. Tompa, D.R. Fitzpatrick, and C.B. Wilson. 2004. Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc. Natl. Acad. Sci. USA. 101:12622-12627.
58. Harant, H., and I.J. Lindley. 2004. Negative cross-talk between the human orphan nuclear receptor Nur77/NAK-1/TR3 and nuclear factor-kappaB. Nucleic Acids Res. 32:5280-5290.
59. Hong, C.Y., J.H. Park, R.S. Ahn, S.Y. Im, H.S. Choi, J. Soh, S.H. Mellon, and K. Lee. 2004. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol. Cell. Biol. 24:2593-2604.
60. Salghetti, S.E., A.A. Caudy, J.G. Chenoweth, and W.P. Tansey. 2001. Regulation of transcriptional activation domain function by ubiquitin. Science. 293:1651-1653.
61. Shaywitz, A.J., and M.E. Greenberg. 1999. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68:821-861.
62. Decker, T., and P. Kovarik. 2000. Serine phosphorylation of STATs. Oncogene. 19:2628-2637.
63. Lee, K.Y., F. D'Acquisto, M.S. Hayden, J.H. Shim, and S. Ghosh. 2005. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science. 308:114-118.
64. Cantrell, D. 1996. T cell antigen receptor signal transduction pathways. Annu. Rev. Immunol. 14:259-274.
65. Kane, L.P., J. Lin, and A. Weiss. 2002. It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol. 23:413-420.
66. Kane, L.P., J. Lin, and A. Weiss. 2000. Signal transduction by the TCR for antigen. Curr. Opin. Immunol. 12:242-249.
67. Voit, R., and I. Grummt. 2001. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc. Natl. Acad. Sci. USA. 98:13631-13636.
68. Pongubala, J.M., C. Van Beveren, S. Nagulapalli, M.J. Klemsz, S.R. McKercher, R.A. Maki, and M.L. Atchison. 1993. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science. 259:1622-1625.
69. Sharma, S., B.R. tenOever, N. Grandvaux, G.P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science. 300:1148-1151.
70. Price, M.A., and D. Kalderon. 2002. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell. 108:823-835.
71. Barker, N., P.J. Morin, and H. Clevers. 2000. The yin-uang of TCF/beta-catenin signaling. Adv. Cancer Res. 77:1-24.
72. Kaytor, M.D., and H.T. Orr. 2002. The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12:275-278.
73. Frame, S., and P. Cohen. 2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:1-16.
74. Harwood, A.J. 2002. Signal transduction in development: holding the key. Dev. Cell. 2:384-385.
75. Okamura, H., C. Garcia-Rodriguez, H. Martinson, J. Qin, D.M. Virshup, and A. Rao. 2004. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol. Cell. Biol. 24:4184-4195.
76. Beals, C.R., C.M. Sheridan, C.W. Turck, P. Gardner, and G.R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 275:1930-1933.